Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE003 (CAN) (Dr. Okafor)
· consented 2022-07-20
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-10-23 (study day 81); relationship: N
moderate
assessed
2026-08-18
Grade 2 Constipation — outcome: UNKNOWN; onset 2022-11-06 (study day 95); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-18 (study day 107); relationship: N
mild
assessed
2026-08-18
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-11-23 (study day 112); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-02-17 (study day 198); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.